Connor, Clark & Lunn Investment Management (CC&L)’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $67.2M | Sell |
135,236
-116,475
| -46% | -$51.6M | 0.13% | 147 |
|
|
2026
Q1 | $112M | Sell |
251,711
-93,672
| -27% | -$43.7M | 0.26% | 86 |
|
|
2025
Q4 | $157M | Buy |
345,383
+124,582
| +56% | +$53.7M | 0.41% | 52 |
|
|
2025
Q3 | $86.5M | Buy |
220,801
+14,706
| +7% | +$6.15M | 0.27% | 61 |
|
|
2025
Q2 | $91.8M | Buy |
206,095
+190,842
| +1,251% | +$87.9M | 0.32% | 58 |
|
|
2025
Q1 | $7.39M | Sell |
15,253
-5,750
| -27% | -$2.68M | 0.03% | 394 |
|
|
2024
Q4 | $8.46M | Buy |
21,003
+13,172
| +168% | +$6.11M | 0.04% | 365 |
|
|
2024
Q3 | $3.64M | Sell |
7,831
-59,554
| -88% | -$28.6M | 0.02% | 517 |
|
|
2024
Q2 | $31.6M | Sell |
67,385
-52,059
| -44% | -$22.6M | 0.13% | 134 |
|
|
2024
Q1 | $49.9M | Buy |
119,444
+51,044
| +75% | +$21.6M | 0.21% | 98 |
|
|
2023
Q4 | $27.8M | Buy |
68,400
+63,303
| +1,242% | +$23.4M | 0.13% | 145 |
|
|
2023
Q3 | $1.77M | Buy |
5,097
+1,197
| +31% | +$419K | 0.01% | 647 |
|
|
2023
Q2 | $1.37M | Sell |
3,900
-1,170
| -23% | -$394K | 0.01% | 704 |
|
|
2023
Q1 | $1.6M | Sell |
5,070
-6,096
| -55% | -$1.83M | 0.01% | 604 |
|
|
2022
Q4 | $3.22M | Sell |
11,166
-17,269
| -61% | -$5.26M | 0.02% | 442 |
|
|
2022
Q3 | $8.23M | Sell |
28,435
-31,266
| -52% | -$9M | 0.05% | 239 |
|
|
2022
Q2 | $16.8M | Buy |
59,701
+29,513
| +98% | +$7.9M | 0.1% | 148 |
|
|
2022
Q1 | $7.88M | Buy |
30,188
+7,955
| +36% | +$1.89M | 0.04% | 254 |
|
|
2021
Q4 | $4.88M | Sell |
22,233
-2,476
| -10% | -$481K | 0.02% | 343 |
|
|
2021
Q3 | $4.48M | Buy |
24,709
+6,257
| +34% | +$1.22M | 0.02% | 356 |
|
|
2021
Q2 | $3.72M | Sell |
18,452
-3,722
| -17% | -$779K | 0.02% | 420 |
|
|
2021
Q1 | $4.76M | Sell |
22,174
-3,314
| -13% | -$728K | 0.03% | 366 |
|
|
2020
Q4 | $6.02M | Sell |
25,488
-27,767
| -52% | -$6.37M | 0.04% | 298 |
|
|
2020
Q3 | $14.5M | Sell |
53,255
-38,396
| -42% | -$10.6M | 0.1% | 161 |
|
|
2020
Q2 | $26.6M | Sell |
91,651
-5,417
| -6% | -$1.47M | 0.19% | 101 |
|
|
2020
Q1 | $23.1M | Buy |
97,068
+45,735
| +89% | +$10.5M | 0.21% | 92 |
|
|
2019
Q4 | $11.2M | Buy |
51,333
+37,508
| +271% | +$7.59M | 0.08% | 172 |
|
|
2019
Q3 | $2.34M | Buy |
13,825
+875
| +7% | +$155K | 0.02% | 385 |
|
|
2019
Q2 | $2.38M | Buy |
12,950
+2,625
| +25% | +$459K | 0.02% | 404 |
|
|
2019
Q1 | $1.9M | Buy |
10,325
+3,725
| +56% | +$688K | 0.01% | 418 |
|
|
2018
Q4 | $1.09M | Sell |
6,600
-21,950
| -77% | -$3.8M | 0.01% | 535 |
|
|
2018
Q3 | $5.5M | Sell |
28,550
-13,899
| -33% | -$2.47M | 0.03% | 302 |
|
|
2018
Q2 | $7.21M | Buy |
42,449
+31,499
| +288% | +$4.88M | 0.04% | 255 |
|
|
2018
Q1 | $1.78M | Sell |
10,950
-2,475
| -18% | -$404K | 0.01% | 401 |
|
|
2017
Q4 | $2.01M | Buy |
13,425
+75
| +0.6% | +$11.1K | 0.01% | 418 |
|
|
2017
Q3 | $2.03M | Buy |
13,350
+3,350
| +34% | +$504K | 0.01% | 419 |
|
|
2017
Q2 | $1.29M | Buy |
10,000
+5,800
| +138% | +$698K | 0.01% | 458 |
|
|
2017
Q1 | $459K | Buy |
+4,200
| New | +$370K | ﹤0.01% | 640 |
|
|
2016
Q2 | – | Sell |
-6,700
| Closed | -$533K | – | 938 |
|
|
2016
Q1 | $533K | Buy |
6,700
+2,500
| +60% | +$226K | ﹤0.01% | 558 |
|
|
2015
Q4 | $528K | Sell |
4,200
-5,100
| -55% | -$616K | ﹤0.01% | 534 |
|
|
2015
Q3 | $969K | Buy |
+9,300
| New | +$1.19M | 0.01% | 410 |
|
|
2014
Q3 | – | Sell |
-25,510
| Closed | -$2.57M | – | 582 |
|
|
2014
Q2 | $2.57M | Sell |
25,510
-202,600
| -89% | -$14.2M | 0.02% | 219 |
|
|
2014
Q1 | $17.8M | Buy |
228,110
+103,500
| +83% | +$8.2M | 0.13% | 87 |
|
|
2013
Q4 | $9.84M | Buy |
124,610
+110,760
| +800% | +$7.71M | 0.08% | 107 |
|
|
2013
Q3 | $1.08M | Buy |
+13,850
| New | +$1.1M | 0.01% | 261 |
|
Other funds holding VRTX
Connor, Clark & Lunn Investment Management (CC&L)'s VRTX Position: Q2 2026 in Review
Connor, Clark & Lunn Investment Management (CC&L) reduced its Vertex Pharmaceuticals (VRTX) stake by 46% in Q2 2026, selling an estimated $51.6M and leaving 135,236 shares worth $67.2M. The position accounts for 0.13% of the portfolio, ranked #147.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VRTX in Q3 2013 and has held it in 45 quarters since. The position peaked at $157M in Q4 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) held 135,236 shares of Vertex Pharmaceuticals worth $67.2M as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) sold 116,475 Vertex Pharmaceuticals shares in Q2 2026, an estimated $51.6M.
- Vertex Pharmaceuticals made up 0.13% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #147 holding.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 45 quarters since.
- Connor, Clark & Lunn Investment Management (CC&L)'s Vertex Pharmaceuticals position peaked at $157M in Q4 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.